Trial · NCT02170532
Aerosolized Beta-Agonist Isomers in Asthma
NCT02170532, Phase 4, Completed, Duke University; results first posted 2014-08-04
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Aerosolized Beta-Agonist Isomers in Asthma. Trials, record NCT02170532. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02170532
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Aerosolized Beta-Agonist Isomers in Asthma
- NCT number
- NCT02170532
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 10 participants, actual
- Lead sponsor
- Duke University
- Conditions
- Asthma
- Interventions
- levalbuterol, saline, levalbuterol MDI, breath actuated nebulizer, aerochamber max, ipratroprium
- First posted
- 2014-06-23
- Last updated
- 2014-08-13
- Results first posted
- 2014-08-04
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Maximum Forced Expiratory Volume at One Second (FEV1) | Baseline (before treatment), 30 minutes, 1, 2, 4, 6, and 8 hours post treatment | |
| Secondary | Change in 8 Hour Area-under-the-curve FEV1 | 0 to 8 hours post dose | |
| Secondary | Change in Heart Rate | Baseline (before treatment), 30 minutes, 1, 2, 4, 6, and 8 hours post treatment | |
| Secondary | Change in Tremor Assessment Measured by a Scale | Baseline (before treatment), 30 minutes, 1, 2, 4, 6, and 8 hours post treatment | Tremor assessment will be made on outstretched hands (0 = none, 1+ = fine tremor, barely perceptible, 2+ = obvious tremor). |
| Secondary | Change in Dyspnea Response as Measured by the University of California, San Diego (UCSD) Dyspnea Scale | Baseline (before treatment), 30 minutes, 1, 2, 4, 6, and 8 hours post treatment |
Source ClinicalTrials.gov
Outcomes5
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Maximum Forced Expiratory Volume at One Second (FEV1) | Baseline (before treatment), 30 minutes, 1, 2, 4, 6, and 8 hours post treatment | The same 10 subjects received each of the 5 treatments in the same order. Subjects 1-5 were not included in 6 and 8 hour time points. | percentage of change | MEAN |
| SECONDARY | Change in 8 Hour Area-under-the-curve FEV1 | 0 to 8 hours post dose | percentage of change | MEAN | |
| SECONDARY | Change in Heart Rate | Baseline (before treatment), 30 minutes, 1, 2, 4, 6, and 8 hours post treatment | Data for this outcome measure is not reported because the data was not collected. | ||
| SECONDARY | Change in Tremor Assessment Measured by a Scale | Baseline (before treatment), 30 minutes, 1, 2, 4, 6, and 8 hours post treatment | Data for this outcome measure is not reported because the data was not collected. | ||
| SECONDARY | Change in Dyspnea Response as Measured by the University of California, San Diego (UCSD) Dyspnea Scale | Baseline (before treatment), 30 minutes, 1, 2, 4, 6, and 8 hours post treatment | Data for this outcome measure is not reported because the data was not collected. |
Source ClinicalTrials.gov
Results by group35
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Maximum Forced Expiratory Volume at One Second (FEV1) | Levalbuterol + Saline in a Breath Actuated Nebulizer | 30 minutes | 20 | Standard Deviation 23.19 | percentage of change |
| Change in Maximum Forced Expiratory Volume at One Second (FEV1) | Levalbuterol + Ipratroprium in a Breath Actuated Nebulizer | 30 minutes | 20 | Standard Deviation 16.55 | percentage of change |
| Change in Maximum Forced Expiratory Volume at One Second (FEV1) | Levalbuterol Metered Dose Inhaler (MDI) 2 Puffs | 30 minutes | 20 | Standard Deviation 19.85 | percentage of change |
| Change in Maximum Forced Expiratory Volume at One Second (FEV1) | Levalbuterol MDI + Aerochamber Max Without Pause 2 Puffs | 30 minutes | 19 | Standard Deviation 20.64 | percentage of change |
| Change in Maximum Forced Expiratory Volume at One Second (FEV1) | Levalbuterol MDI + Aerochamber Max With 2 Second Pause 2 Puffs | 30 minutes | 21 | Standard Deviation 21.10 | percentage of change |
| Change in Maximum Forced Expiratory Volume at One Second (FEV1) | Levalbuterol + Saline in a Breath Actuated Nebulizer | 1 hour | 28 | Standard Deviation 31.45 | percentage of change |
| Change in Maximum Forced Expiratory Volume at One Second (FEV1) | Levalbuterol + Ipratroprium in a Breath Actuated Nebulizer | 1 hour | 23 | Standard Deviation 19.24 | percentage of change |
| Change in Maximum Forced Expiratory Volume at One Second (FEV1) | Levalbuterol Metered Dose Inhaler (MDI) 2 Puffs | 1 hour | 19 | Standard Deviation 22.57 | percentage of change |
| Change in Maximum Forced Expiratory Volume at One Second (FEV1) | Levalbuterol MDI + Aerochamber Max Without Pause 2 Puffs | 1 hour | 20 | Standard Deviation 24.23 | percentage of change |
| Change in Maximum Forced Expiratory Volume at One Second (FEV1) | Levalbuterol MDI + Aerochamber Max With 2 Second Pause 2 Puffs | 1 hour | 24 | Standard Deviation 22.62 | percentage of change |
1 to 10 of 35Source ClinicalTrials.gov
See all 35 results by groupParticipant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | All Subjects | 10 | |
| Overall Study | COMPLETED | All Subjects | 10 | |
| Overall Study | NOT COMPLETED | All Subjects | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | All Subjects | ||
| Total, other adverse events | All Subjects | 0 | 10 |
| Total, serious adverse events | All Subjects | 0 | 10 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02170532
GET https://conductscience.org/api/trials/v1/NCT02170532/results?page=2